<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199536</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-GRU-NEX-2009/1</org_study_id>
    <nct_id>NCT01199536</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers</brief_title>
  <official_title>Observational Study to Evaluate Helicobacter Pylori Eradication at the End of Routine Triple Eradication Therapy With Duodenal Ulcer Relapses Control.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study purpose is to evaluate Helicobacter pylori susceptibility to Clarithromycin and to
      estimate eradication and healing rates of duodenal ulcer routine eradication therapy at the
      end of treatment and 52 weeks from the therapy start
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of H. pylori at the end routine triple eradication therapy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of duodenal ulcer (in patients with ulcer defects in inclusion stage)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of duodenal ulcer relapses</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency of duodenal ulcer relapses based on gastroscopy data and recurrence rate of H.Pylori infection based on breath test data after 52 weeks from the start of the therapy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">59</enrollment>
  <condition>Duodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients with Helicobacter-positive duodenal ulcer</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for Hematology (whole blood) and Chemistry (serum), gasric mucosa biopsies
      taken during esophagogastroduodenoscopy (EGDS) in routine practice of Moscow Medical Academy
      n/a I.M. Sechenov, Moscow State Medical and Stomatological University, Central Clinical
      Hospital of Presidential Administration
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active duodenal ulcer with duodenal ulcer exacerbation confirmed by endoscopic signs
             of duodenal ulcer disease (acute ulcer or scar deformity of the duodenal bulb) and
             anamnesis data.

          -  Helicobacter pylori positive diagnosis at entry by 13C-Urea Breath Test (UBT)

          -  Prescription of the standard 7-day eradication therapy including esomeprazole 20 mg
             bd, amoxicillin 1000 mg bd, clarithromycin 500 mg bd

          -  Written informed consent provided prior the start of participation in the study.

        Exclusion Criteria:

          -  Subjects who are unwilling or unable to provide informed consent

          -  Current complication of duodenal ulcer disease, e.g. perforation, bleeding or pyloric
             stenosis

          -  History of esophageal/gastric/duodenal surgery except of the patients underwent
             perforated ulcer closure or endoscopic hemostasis more than 6 months ago

          -  Contraindications to Esomeprazole, Amoxicillin or Clarythromycin including known or
             suspected hypersensitivity or allergy

          -  Treatment with Amoxicillin, Clarythromycin or Bismuth containing drugs one month prior
             to inclusion

          -  Two or more previous attempts to eradicate H. Pylori
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir T. Ivashkin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Chair of Internal Diseases Propedeutics and Gastroenterology at MMA n/a I.M. Sechenov</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter-positive duodenal ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Duodenal Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

